Shionogi and F2G report positive top line data from Phase III OASIS study

Shionogi and F2G have reported positive top line data from the global OASIS Phase III study evaluating oral antifungal drug olorofim. Shionogi and F2G are jointly developing and commercialising olorofim for invasive fungal infections. Credit: Tapati Rinchumrus / Shutterstock.com. Shionogi and F2G have reported positive top line data from the global OASIS Phase III study evaluating oral antifungal drug olorofim, compared with AmBisome followed by standard of care (SOC) in adults with invasive aspergillosis whose infection is refractory to or unsuitable for azole therapy. The randomised, global study achieved its primary endpoint, demonstrating non-inferiority for olorofim with an all-cause mortality…

Source: Clinical Trials Arena